Chief Executive Officer

Dr. Sloan is a seasoned global executive with a proven track record of leading organizations, building high-performing cross-functional teams, and driving successful execution of drug development programs. With extensive experience in executive leadership, licensing, fundraising, and strategic portfolio management, Dr. Sloan has led efforts across multiple therapeutic areas, including rare diseases, oncology, and cardiovascular, as well as various modalities such as small molecules, peptides, and biologics.

Her expertise spans from executive strategy to R&D strategy and operational leadership, culminating in multiple successful BLA and NDA submissions. Dr. Sloan has played a key role in the regulatory approvals of several high-impact therapies, including Loargys® (pegzilarginase), Somatuline® Depot (lanreotide), Dysport® (abotulinumtoxinA), and XERMELO® (telotristat ethyl).

Before joining OmniNano, Dr. Sloan served as the SVP of Development and Operations at PanTher Therapeutics, where she led execution of the lead program, cross-functional collaboration, operational excellence, and resource management. Dr. Sloan successfully guided the development and execution of PanTher’s first IND, which earned FDA clearance.

 Prior to PanTher, Leslie served as Chief Operating Officer for Aeglea Biotherapeutics, a human enzyme therapeutics company. During her time at Aeglea, she oversaw portfolio programs from discovery through clinical development to achieve scientific, medical, and financial objectives. Previously, Leslie held several global leadership roles at Ipsen and Pfizer. While at Ipsen, she provided strategic and operational leadership for a global R&D portfolio focused on cancer, neuroscience, and rare diseases. She also served as the President Ipsen Bioscience. Leslie holds PhD and MS degrees in Bioorganic Chemistry from Yale University and a BS in Chemistry and Medical Biology from Southeastern Oklahoma State University.